{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:47:23Z","timestamp":1794653243002,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-03524"],"award-info":[{"award-number":["2021-03524"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-01083"],"award-info":[{"award-number":["2021-01083"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007464","name":"Torsten S\u00f6derbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transferrin receptor\u00a01 (TfR1) mediated brain delivery of antibodies could become important for increasing the efficacy of emerging immunotherapies in Alzheimer's disease (AD). However, age, dose, binding to TfR1 on blood cells, and pathology could influence the TfR1-mediated transcytosis of TfR1-binders across the blood\u2013brain barrier (BBB). The aim of the study was, therefore, to investigate the impact of these factors on the brain delivery of a bispecific TfR1-transported A\u03b2-antibody, mAb3D6-scFv8D3, in comparison with the conventional antibody mAb3D6.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Young (3\u20135\u00a0months) and aged (17\u201320\u00a0months) WT and tg-ArcSwe mice (AD model) were injected with <jats:sup>125<\/jats:sup>I-labeled mAb3D6-scFv8D3 or mAb3D6. Three different doses were used in the study, 0.05\u00a0mg\/kg (low dose), 1\u00a0mg\/kg (high dose), and 10\u00a0mg\/kg (therapeutic dose), with equimolar doses for mAb3D6. The dose-corrected antibody concentrations in whole blood, blood cells, plasma, spleen, and brain were evaluated at 2\u00a0h post-administration. Furthermore, isolated brains were studied by autoradiography, nuclear track emulsion, and capillary depletion to investigate the intrabrain distribution of the antibodies, while binding to blood cells was studied in vitro using blood isolated from young and aged mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The aged WT and tg-ArcSwe mice showed significantly lower brain concentrations of TfR-binding [<jats:sup>125<\/jats:sup>I]mAb3D6-scFv8D3 and higher concentrations in the blood cell fraction compared to young mice. For [<jats:sup>125<\/jats:sup>I]mAb3D6, no significant differences in blood or brain delivery were observed between young and aged mice or between genotypes. A low dose of [<jats:sup>125<\/jats:sup>I]mAb3D6-scFv8D3 was associated with increased relative parenchymal delivery, as well as increased blood cell distribution. Brain concentrations and relative parenchymal distribution of [<jats:sup>125<\/jats:sup>I]mAb3D6-scFv8D6 did not differ between tg-ArcSwe and WT mice at this early time point but were considerably increased compared to those observed for [<jats:sup>125<\/jats:sup>I]mAb3D6.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Age-dependent differences in blood and brain concentrations were observed for the bispecific antibody mAb3D6-scFv8D3 but not for the conventional A\u03b2 antibody mAb3D6, indicating an age-related effect on TfR1-mediated brain delivery. The lowest dose of [<jats:sup>125<\/jats:sup>I]mAb3D6-scFv8D3 was associated with higher relative BBB penetration but, at the same time, a higher distribution to blood cells. Overall, A\u03b2-pathology did not influence the early brain distribution of the bispecific antibody. In summary, age and bispecific antibody dose were important factors determining brain delivery, while genotype was not.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12987-023-00435-2","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:04:13Z","timestamp":1683795853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody"],"prefix":"10.1186","volume":"20","author":[{"given":"Rebecca","family":"Faresj\u00f6","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Sehlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"435_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, et al. Immunotherapy for Alzheimer\u2019s disease: targeting \u03b2-amyloid and beyond. Transl Neurodegener. 2022;11:18.","journal-title":"Transl Neurodegener"},{"key":"435_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res Ther. 2020;12:95.","journal-title":"Alzheimers Res Ther"},{"key":"435_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11602-8","author":"M Edwards","year":"2023","unstructured":"Edwards M, Corkill R. Disease-modifying treatments in Alzheimer\u2019s disease. J Neurol. 2023. https:\/\/doi.org\/10.1007\/s00415-023-11602-8.","journal-title":"J Neurol"},{"key":"435_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1021\/mp900235k","volume":"7","author":"RJ Boado","year":"2010","unstructured":"Boado RJ, Zhou Q-H, Lu JZ, Hui EK-W, Pardridge WM. Pharmacokinetics and brain uptake of a genetically engineered bi-functional fusion antibody targeting the mouse transferrin receptor. Mol Pharm. 2010;7:237\u201344.","journal-title":"Mol Pharm"},{"key":"435_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","volume":"9","author":"T Gustavsson","year":"2020","unstructured":"Gustavsson T, Syv\u00e4nen S, O\u2019Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-\u03b2 antibody in a mouse model of Alzheimer\u2019s disease. Transl Neurodegener. 2020;9:37.","journal-title":"Transl Neurodegener"},{"key":"435_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syv\u00e4nen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7:308\u201318.","journal-title":"Theranostics"},{"key":"435_CR7","first-page":"1048","volume":"292","author":"HJ Lee","year":"2000","unstructured":"Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;292:1048\u201352.","journal-title":"J Pharmacol Exp Ther"},{"key":"435_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-130029","volume":"37","author":"K Magnusson","year":"2013","unstructured":"Magnusson K, Sehlin D, Syv\u00e4nen S, Svedberg MM, Philipson O, S\u00f6derberg L, et al. Specific uptake of an amyloid-\u03b2 protofibril-binding antibody-tracer in A\u03b2PP transgenic mouse brain. J Alzheimers Dis. 2013;37:29\u201340.","journal-title":"J Alzheimers Dis"},{"key":"435_CR9","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/ncomms10759","volume":"7","author":"D Sehlin","year":"2016","unstructured":"Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syv\u00e4nen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease. Nat Commun. 2016;7:10759.","journal-title":"Nat Commun"},{"key":"435_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","volume":"10","author":"S Syv\u00e4nen","year":"2018","unstructured":"Syv\u00e4nen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, S\u00f6derberg L, et al. Efficient clearance of A\u03b2 protofibrils in A\u03b2PP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10:49.","journal-title":"Alzheimers Res Ther"},{"key":"435_CR11","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.","journal-title":"Sci Transl Med."},{"key":"435_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"435_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"435_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.01019","author":"VM Pulgar","year":"2019","unstructured":"Pulgar VM. Transcytosis to cross the blood brain barrier new advancements and challenges. Front Neurosci. 2019. https:\/\/doi.org\/10.3389\/fnins.2018.01019.","journal-title":"Front Neurosci"},{"key":"435_CR15","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/j.1471-4159.1990.tb04886.x","volume":"54","author":"D Triguero","year":"1990","unstructured":"Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem. 1990;54:1882\u20138.","journal-title":"J Neurochem"},{"key":"435_CR16","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1038\/s41598-017-11220-1","volume":"7","author":"KB Johnsen","year":"2017","unstructured":"Johnsen KB, Burkhart A, Melander F, Kempen PJ, Vejlebo JB, Siupka P, et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;7:10396.","journal-title":"Sci Rep"},{"key":"435_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1359","author":"MS Kariolis","year":"2020","unstructured":"Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aay1359.","journal-title":"Sci Transl Med"},{"key":"435_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49\u201360.","journal-title":"Neuron"},{"key":"435_CR19","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.93","author":"E Siemers","year":"2022","unstructured":"Siemers E, Hitchcock J, Sundell K, Dean R, Jerecic J, Cline E, et al. ACU193, a monoclonal antibody that selectively binds soluble A\u03b2 oligomers: development rationale, phase 1 trial design and clinical development plan. J Prev Alzheimers Dis. 2022. https:\/\/doi.org\/10.14283\/jpad.2022.93.","journal-title":"J Prev Alzheimers Dis"},{"key":"435_CR20","doi-asserted-by":"publisher","first-page":"2057269","DOI":"10.1080\/19420862.2022.2057269","volume":"14","author":"P Zhao","year":"2022","unstructured":"Zhao P, Anami Y, Gao P, Fan X, Li L, Tsuchikama K, et al. Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. MAbs. 2022;14:2057269.","journal-title":"MAbs"},{"key":"435_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.039","author":"T Okuyama","year":"2020","unstructured":"Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M, et al. A phase 2\/3 trial of Pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2020. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.039.","journal-title":"Mol Ther"},{"key":"435_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","volume":"27","author":"T Okuyama","year":"2019","unstructured":"Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial. Mol Ther. 2019;27:456\u201364.","journal-title":"Mol Ther"},{"key":"435_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021;20:362\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"435_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefferies","year":"1984","unstructured":"Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312:162\u20133.","journal-title":"Nature"},{"key":"435_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF02982790","volume":"76","author":"Y Kohgo","year":"2002","unstructured":"Kohgo Y, Torimoto Y, Kato J. Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor. Int J Hematol. 2002;76:213\u20138.","journal-title":"Int J Hematol"},{"key":"435_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00034","author":"CA Worthen","year":"2014","unstructured":"Worthen CA, Enns CA. The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body. Front Pharmacol. 2014. https:\/\/doi.org\/10.3389\/fphar.2014.00034.","journal-title":"Front Pharmacol"},{"key":"435_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","volume":"133","author":"H Kawabata","year":"2019","unstructured":"Kawabata H. Transferrin and transferrin receptors update. Free Radic Biol Med. 2019;133:46\u201354.","journal-title":"Free Radic Biol Med"},{"key":"435_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/ajh.24421","volume":"91","author":"MM Rhodes","year":"2016","unstructured":"Rhodes MM, Koury ST, Kopsombut P, Alford CE, Price JO, Koury MJ. Stress reticulocytes lose transferrin receptors by an extrinsic process involving spleen and macrophages. Am J Hematol. 2016;91:875\u201382.","journal-title":"Am J Hematol"},{"key":"435_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bcmd.2018.06.004","volume":"72","author":"R Thomson-Luque","year":"2018","unstructured":"Thomson-Luque R, Wang C, Ntumngia FB, Xu S, Szekeres K, Conway A, et al. In-depth phenotypic characterization of reticulocyte maturation using mass cytometry. Blood Cells Mol Dis. 2018;72:22\u201333.","journal-title":"Blood Cells Mol Dis"},{"key":"435_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, et al. Lack of widespread BBB disruption in Alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron. 2015;88:289\u201397.","journal-title":"Neuron"},{"key":"435_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1021\/acs.molpharmaceut.8b00870","volume":"16","author":"P Bourassa","year":"2019","unstructured":"Bourassa P, Alata W, Tremblay C, Paris-Robidas S, Calon F. Transferrin receptor-mediated uptake at the blood-brain barrier is not impaired by alzheimer\u2019s disease neuropathology. Mol Pharm. 2019;16:583\u201394.","journal-title":"Mol Pharm"},{"key":"435_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13311-018-0656-x","volume":"15","author":"AA Belaidi","year":"2018","unstructured":"Belaidi AA, Gunn AP, Wong BX, Ayton S, Appukuttan AT, Roberts BR, et al. Marked age-related changes in brain iron homeostasis in amyloid protein precursor knockout mice. Neurotherapeutics. 2018;15:1055\u201362.","journal-title":"Neurotherapeutics"},{"key":"435_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2453-z","volume":"583","author":"AC Yang","year":"2020","unstructured":"Yang AC, Stevens MY, Chen MB, Lee DP, St\u00e4hli D, Gate D, et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature. 2020;583:425\u201330.","journal-title":"Nature"},{"key":"435_CR34","doi-asserted-by":"publisher","first-page":"183ra57","DOI":"10.1126\/scitranslmed.3005338","volume":"5","author":"JA Couch","year":"2013","unstructured":"Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013;5:183ra57.","journal-title":"Sci Transl Med."},{"key":"435_CR35","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6:261ra154.","journal-title":"Sci Transl Med."},{"key":"435_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11095-022-03172-7","volume":"39","author":"SG Summerfield","year":"2022","unstructured":"Summerfield SG, Yates JWT, Fairman DA. Free drug theory\u2014no longer just a hypothesis? Pharm Res. 2022;39:213\u201322.","journal-title":"Pharm Res"},{"key":"435_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12987-021-00257-0","volume":"18","author":"R Faresj\u00f6","year":"2021","unstructured":"Faresj\u00f6 R, Bonvicini G, Fang XT, Aguilar X, Sehlin D, Syv\u00e4nen S. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS. 2021;18:26.","journal-title":"Fluids Barriers CNS"},{"key":"435_CR38","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1021\/acs.molpharmaceut.2c00536","volume":"19","author":"E Schlein","year":"2022","unstructured":"Schlein E, Syv\u00e4nen S, Rokka J, Gustavsson T, Rossin R, Robillard M, et al. Functionalization of radiolabeled antibodies to enhance peripheral clearance for high contrast brain imaging. Mol Pharm. 2022;19:4111\u201322.","journal-title":"Mol Pharm"},{"key":"435_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neurobiolaging.2004.12.007","volume":"27","author":"A Lord","year":"2006","unstructured":"Lord A, Kalimo H, Eckman C, Zhang X-Q, Lannfelt L, Nilsson LNG. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67\u201377.","journal-title":"Neurobiol Aging"},{"key":"435_CR40","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.neurobiolaging.2007.11.022","volume":"30","author":"O Philipson","year":"2009","unstructured":"Philipson O, Hammarstr\u00f6m P, Nilsson KPR, Portelius E, Olofsson T, Ingelsson M, et al. A highly insoluble state of A\u03b2 similar to that of Alzheimer\u2019s disease brain is found in Arctic APP transgenic mice. Neurobiol Aging. 2009;30:1393\u2013405.","journal-title":"Neurobiol Aging"},{"key":"435_CR41","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916\u20139.","journal-title":"Nat Med"},{"key":"435_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s004180050266","volume":"110","author":"K Kissel","year":"1998","unstructured":"Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C, Engelhardt B. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol. 1998;110:63\u201372.","journal-title":"Histochem Cell Biol"},{"key":"435_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/alzrt261","volume":"6","author":"H Feinberg","year":"2014","unstructured":"Feinberg H, Saldanha JW, Diep L, Goel A, Widom A, Veldman GM, et al. Crystal structure reveals conservation of amyloid-\u03b2 conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther. 2014;6:31.","journal-title":"Alzheimers Res Ther"},{"key":"435_CR44","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1073\/pnas.94.4.1550","volume":"94","author":"K Johnson-Wood","year":"1997","unstructured":"Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"435_CR45","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/srep01302","volume":"3","author":"LA Miles","year":"2013","unstructured":"Miles LA, Crespi GAN, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation. Sci Rep. 2013;3:1302.","journal-title":"Sci Rep"},{"key":"435_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12575-017-0060-7","volume":"19","author":"XT Fang","year":"2017","unstructured":"Fang XT, Sehlin D, Lannfelt L, Syv\u00e4nen S, Hultqvist G. Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biol Proced Online. 2017;19:11.","journal-title":"Biol Proced Online"},{"key":"435_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1042\/bj0890114","volume":"89","author":"FC Greenwood","year":"1963","unstructured":"Greenwood FC, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J. 1963;89:114\u201323.","journal-title":"Biochem J"},{"key":"435_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","volume":"55","author":"EG Gutierrez","year":"1994","unstructured":"Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol. 1994;55:153\u201360.","journal-title":"J Neuroimmunol"},{"key":"435_CR49","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1007\/s00259-019-04426-0","volume":"46","author":"D Sehlin","year":"2019","unstructured":"Sehlin D, Syv\u00e4nen S. Engineered antibodies: new possibilities for brain PET? Eur J Nucl Med Mol Imaging. 2019;46:2848\u201358.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"435_CR50","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1038\/s41598-020-60438-z","volume":"10","author":"JS Ruano-Salguero","year":"2020","unstructured":"Ruano-Salguero JS, Lee KH. Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn. Sci Rep. 2020;10:3685. https:\/\/doi.org\/10.1038\/s41598-020-60438-z.","journal-title":"Sci Rep"},{"key":"435_CR51","doi-asserted-by":"publisher","first-page":"H1370","DOI":"10.1152\/ajpheart.00709.2020","volume":"320","author":"\u00c1 Ny\u00fal-T\u00f3th","year":"2021","unstructured":"Ny\u00fal-T\u00f3th \u00c1, Tarantini S, DelFavero J, Yan F, Balasubramanian P, Yabluchanskiy A, et al. Demonstration of age-related blood-brain barrier disruption and cerebromicrovascular rarefaction in mice by longitudinal intravital two-photon microscopy and optical coherence tomography. Am J Physiol Heart Circ Physiol. 2021;320:H1370\u201392.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"435_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12979-015-0029-9","volume":"12","author":"M Elahy","year":"2015","unstructured":"Elahy M, Jackaman C, Mamo JC, Lam V, Dhaliwal SS, Giles C, et al. Blood\u2013brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing. 2015;12:2.","journal-title":"Immun Ageing"},{"key":"435_CR53","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.mad.2007.07.002","volume":"128","author":"C Pelegr\u00ed","year":"2007","unstructured":"Pelegr\u00ed C, Canudas AM, del Valle J, Casadesus G, Smith MA, Camins A, et al. Increased permeability of blood\u2013brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev. 2007;128:522\u20138.","journal-title":"Mech Ageing Dev"},{"key":"435_CR54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.mvr.2009.06.009","volume":"78","author":"S Bake","year":"2009","unstructured":"Bake S, Friedman JA, Sohrabji F. Reproductive age-related changes in the blood brain barrier: Expression of IgG and tight junction proteins. Microvasc Res. 2009;78:413\u201324.","journal-title":"Microvasc Res"},{"key":"435_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","volume":"143","author":"S Gustafsson","year":"2018","unstructured":"Gustafsson S, Gustavsson T, Roshanbin S, Hultqvist G, Hammarlund-Udenaes M, Sehlin D, et al. Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;143:1\u20139.","journal-title":"Neuropharmacology"},{"issue":"3","key":"435_CR56","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1021\/acs.molpharmaceut.2c00768","volume":"20","author":"JI Morrison","year":"2023","unstructured":"Morrison JI, Petrovic A, Metzendorf NG, Yilmaz CU, Stenler S, Laudon H, et al. A standardised pre-clinical in-vitro blood-brain barrier mouse assay validates endocytosis dependent antibody transcytosis using transferrin receptor-mediated pathways. Mol Pharm. 2023;20(3):1564\u201376.","journal-title":"Mol Pharm"},{"key":"435_CR57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/jcmm.13980","volume":"23","author":"LC Ceafalan","year":"2019","unstructured":"Ceafalan LC, Fertig TE, Gheorghe TC, Hinescu ME, Popescu BO, Pahnke J, et al. Age-related ultrastructural changes of the basement membrane in the mouse blood-brain barrier. J Cell Mol Med. 2019;23:819\u201327.","journal-title":"J Cell Mol Med"},{"key":"435_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-011-0801-7","volume":"121","author":"CA Hawkes","year":"2011","unstructured":"Hawkes CA, H\u00e4rtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011;121:431\u201343.","journal-title":"Acta Neuropathol"},{"key":"435_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/0271678X15608396","volume":"36","author":"PC Nahirney","year":"2016","unstructured":"Nahirney PC, Reeson P, Brown CE. Ultrastructural analysis of blood\u2013brain barrier breakdown in the peri-infarct zone in young adult and aged mice. J Cereb Blood Flow Metab. 2016;36:413\u201325.","journal-title":"J Cereb Blood Flow Metab."},{"key":"435_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mrgentox.2009.02.002","volume":"675","author":"SD Dertinger","year":"2009","unstructured":"Dertinger SD, Bemis JC, Phonethepswath S, Tsai Y, Nowak I, Hyrien O, et al. Reticulocyte and micronucleated reticulocyte responses to gamma irradiation: Effect of age. Mutat Res. 2009;675:77\u201380.","journal-title":"Mutat Res"},{"key":"435_CR61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0047-6374(88)90061-9","volume":"42","author":"M Magnani","year":"1988","unstructured":"Magnani M, Rossi L, Stocchi V, Cucchiarini L, Piacentini G, Fornaini G. Effect of age on some properties of mice erythrocytes. Mech Ageing Dev. 1988;42:37\u201347.","journal-title":"Mech Ageing Dev"},{"key":"435_CR62","first-page":"249","volume":"116","author":"JM Flanagan","year":"2006","unstructured":"Flanagan JM, Peng H, Wang L, Gelbart T, Lee P, Sasu BJ, et al. Soluble transferrin receptor-1 levels in mice do not affect iron absorption. AHA. 2006;116:249\u201354.","journal-title":"AHA"},{"key":"435_CR63","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0301-472X(01)00641-5","volume":"29","author":"S R\u2019zik","year":"2001","unstructured":"R\u2019zik S, Beguin Y. Serum soluble transferrin receptor concentration is an accurate estimate of the mass of tissue receptors. Exp Hematol. 2001;29:677\u201385.","journal-title":"Exp Hematol."},{"key":"435_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejpb.2016.01.009","volume":"101","author":"K Gadkar","year":"2016","unstructured":"Gadkar K, Yadav DB, Zuchero JY, Couch JA, Kanodia J, Kenrick MK, et al. Mathematical PKPD and safety model of bispecific TfR\/BACE1 antibodies for the optimization of antibody uptake in brain. Eur J Pharm Biopharm. 2016;101:53\u201361.","journal-title":"Eur J Pharm Biopharm"},{"key":"435_CR65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/psp4.12081","volume":"5","author":"J Kanodia","year":"2016","unstructured":"Kanodia J, Gadkar K, Bumbaca D, Zhang Y, Tong R, Luk W, et al. Prospective design of anti-transferrin receptor bispecific antibodies for optimal delivery into the human brain. CPT Pharmacometrics Syst Pharmacol. 2016;5:283\u201391.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"435_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096340","volume":"9","author":"H Sade","year":"2014","unstructured":"Sade H, Baumgartner C, Hugenmatter A, Moessner E, Freskg\u00e5rd P-O, Niewoehner J. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by ph-dependent receptor binding. PLoS One. 2014;9(4): e96340. https:\/\/doi.org\/10.1371\/journal.pone.0096340.","journal-title":"PLoS One."},{"key":"435_CR67","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.118.213140","volume":"59","author":"SR Meier","year":"2018","unstructured":"Meier SR, Syv\u00e4nen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, et al. Antibody-based in vivo PET imaging detects amyloid-\u03b2 reduction in Alzheimer transgenic mice after BACE-1 inhibition. J Nucl Med. 2018;59:1885\u201391.","journal-title":"J Nucl Med"},{"key":"435_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Xiong M, Hultqvist G, S\u00f6derberg L, Zachrisson O, Meier S, et al. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208: 108985.","journal-title":"Neuropharmacology"},{"key":"435_CR69","first-page":"1","volume":"00","author":"JI Morrison","year":"2023","unstructured":"Morrison JI, Metzendorf NG, Rofo F, Petrovic A, Hultqvist G. A single-chain fragment constant design enables easy production of a monovalent blood\u2013brain barrier transporter and provides an improved brain uptake at elevated doses. J Neurochem. 2023;00:1\u201313.","journal-title":"J Neurochem"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-023-00435-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-023-00435-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-023-00435-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T10:08:48Z","timestamp":1683799728000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-023-00435-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1186\/s12987-023-00435-2","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments described in this study were approved by the Uppsala County Animal Ethics board (5.8.18\u201320401\/2020), following the rules and regulations of the Swedish Animal Welfare Agency and complied with the European Communities Council Directive of 22 September 2010 (2010\/63\/EU).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}